Market Overview

Benzinga's Top #PreMarket Gainers

Share:
Related ALNY
Morning Market Gainers
Benzinga's Top #PreMarket Gainers
Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More (Seeking Alpha)
Related MRK
Merck Earnings: The Street And The Crowd Expect A Double-Digit Year-Over-Year Decline
Does Apple Hide More Cash Abroad Than Anyone?
If It Gets Approval Quickly, Merck Could Challenge Gilead Sciences In Hepatitis C (Seeking Alpha)

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares jumped 35.93% to $90.00 in pre-market trading after the company reported that it has acquired investigational RNAi Therapeutic assets from Merck (NYSE: MRK). Genzyme and Alnylam expanded their collaboration on rare genetic diseases.

Beam (NYSE: BEAM) shares gained 25.93% to $84.35 in the pre-market after the company agreed to be acquired by Suntory Holdings for $83.50 per share in cash.

NII Holdings (NASDAQ: NIHD) surged 20.81% to $2.70 in the pre-market session after the company and Telefonica signed agreements to provide wholesale voice and data services to Nextel in Brazil and Mexico.

Clovis Oncology (NASDAQ: CLVS) soared 6.99% to $79.15 in the pre-market trading after the company announced 2014 objectives and financial outlook.

Posted-In: PreMarket GainersNews Pre-Market Outlook Markets Movers

 

Related Articles (ALNY + BEAM)

Around the Web, We're Loving...